Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer

Otolaryngology - Head and Neck Surgery (United States)

Volumn 147, Issue 3, 2012, Pages 493-500

  Judd, Nancy P ^a   Allen, Clint T ^a   Winkler, Ashley E ^a   Uppaluri, Ravindra ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

oral cancer; syngeneic model; tumor infiltrating lymphocytes

Indexed keywords

CARCINOGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL TRANSPLANTATION; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; FLOW CYTOMETRY; HISTOCOMPATIBILITY COMPLEX; IMMUNOCOMPETENCE; ISOGRAFT; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MOUTH CANCER; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PHENOTYPE; STUDY DESIGN; TISSUE CULTURE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UNIVERSITY HOSPITAL;

ANIMALS; ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHENOTYPE; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, ISOGENEIC;

EID: 84870443932     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599812442037     Document Type: Article

References (41)

1. Schmitz S, Machiels JP. Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications. Expert Rev Anticancer Ther. 2010 ; 10: 1471-1484
2. Hauswald H, Simon C, Hecht S, Debus J, Lindel K. Long-term outcome and patterns of failure in patients with advanced head and neck cancer. Radiat Oncol. 2011 ; 6: 70
3. Allen CT, Lewis JS, El-Mofty SK, Haughey BH, Nussenbaum B. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope. 2010 ; 120: 1756-1772
4. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001 ; 410: 1107-1111 (Pubitemid 32391043)
5. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007 ; 370: 59-67 (Pubitemid 47017468)
6. Snyderman CH, Heo DS, Chen K, Whiteside TL, Johnson JT. T-cell markers in tumor-infiltrating lymphocytes of head and neck cancer. Head Neck. 1989 ; 11: 331-336 (Pubitemid 19183536)
7. Pretscher D, Distel LV, Grabenbauer GG, Wittlinger M, Buettner M, Niedobitek G. Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer. 2009 ; 9: 292
8. Thurlow JK, Pena Murillo CL, Hunter KD, et al. Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. J Clin Oncol. 2010 ; 28: 2881-2888
9. Uppaluri R, Dunn GP, Lewis JS. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun. 2008 ; 8: 16
10. Allen C, Judd N, Bui J, Uppaluri R. The clinical implications of anti-tumor immunity in head and neck cancer. Laryngoscope. 2012 ; 122: 144-157
11. Kim S. Animal models of cancer in the head and neck region. Clin Exp Otorhinolaryngol. 2009 ; 2: 55-60
12. Sano D, Myers JN. Xenograft models of head and neck cancers. Head Neck Oncol. 2009 ; 1: 32
13. Judd NP, Winkler AE, Murillo-Sauca OJ, et al. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012 ; 72: 365-274
14. Skarnes WC, Rosen B, West AP, et al. A conditional knockout resource for the genome-wide study of mouse gene function. Nature. 2011 ; 474: 337-342
15. Bui JD, Uppaluri R, Hsieh CS, Schreiber RD. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res. 2006 ; 66: 7301-7309 (Pubitemid 44197712)
16. Bandoh N, Ogino T, Katayama A, et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep. 2010 ; 23: 933-939
17. Ogino T, Shigyo H, Ishii H, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006 ; 66: 9281-9289 (Pubitemid 44521150)
18. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006 ; 12: 3890-3895 (Pubitemid 44078071)
19. Bergmann C, Strauss L, Wang Y, et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res. 2008 ; 14: 3706-3715
20. Chikamatsu K, Sakakura K, Whiteside TL, Furuya N. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck. 2007 ; 29: 120-127 (Pubitemid 46167778)
21. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. 2011 ; 11: 119-130
22. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007 ; 13: 6301-6311 (Pubitemid 350075018)
23. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007 ; 13: 4345-4354 (Pubitemid 47219698)
24. Schott AK, Pries R, Wollenberg B. Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. Int J Mol Med. 2010 ; 26: 67-75
25. Badoual C, Hans S, Rodriguez J, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006 ; 12: 465-472 (Pubitemid 43166137)
26. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007 ; 104: 973-978 (Pubitemid 46154721)
27. Chikamatsu K, Takahashi G, Sakakura K, Ferrone S, Masuyama K. Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck. 2011 ; 33: 208-215
28. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008 ; 27: 5904-5912
29. Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev. 2006 ; 17: 141-146 (Pubitemid 43949076)
30. Tanaka K, Jinhua P, Omura K, Azuma M. Multipotency of CD11bhighGr-1+ immature myeloid cells accumulating in oral squamous cell carcinoma-bearing mice. Oral Oncol. 2007 ; 43: 586-592 (Pubitemid 46856267)
31. Nagaraj S, Collazo M, Corzo CA, et al. Regulatory myeloid suppressor cells in health and disease. Cancer Res. 2009 ; 69: 7503-7506
32. Young MR. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck. 2006 ; 28: 462-470 (Pubitemid 43673082)
33. Young MR, Lathers DM. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol. 1999 ; 21: 241-252 (Pubitemid 29241776)
34. Young MR, Wright MA, Lozano Y, et al. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer. 1997 ; 74: 69-74 (Pubitemid 27157858)
35. Watanabe S, Deguchi K, Zheng R, et al. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol. 2008 ; 181: 3291-3300
36. Marcus B, Arenberg D, Lee J, et al. Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer. 2004 ; 101: 2779-2787
37. Rittà M, De Andrea M, Mondini M, et al. Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression. Head Neck. 2009 ; 31: 318-327
38. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008 ; 18: 349-355
39. Thomas GR, Chen Z, Oechsli MN, Hendler FJ, Van Waes C. Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int J Cancer. 1999 ; 82: 377-384 (Pubitemid 29302979)
40. Hoover AC, Spanos WC, Harris GF, Anderson ME, Klingelhutz AJ, Lee JH. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Arch Otolaryngol Head Neck Surg. 2007 ; 133: 495-502 (Pubitemid 46799788)
41. O'Malley BW, Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg. 1997 ; 123: 20-24 (Pubitemid 27043653)